PAG
ESPR

Private Advisor Group’s Esperion Therapeutics ESPR Stock Holding History

Private Advisor Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Sell
32,381
-6,225
-16% -$17.4K ﹤0.01% 2439
2026
Q1 		$106K Hold
38,606
– – ﹤0.01% 2527
2025
Q4 		$143K Sell
38,606
-15,000
-28% -$48.5K ﹤0.01% 2445
2025
Q3 		$142K Buy
53,606
+13,500
+34% +$26.1K ﹤0.01% 2382
2025
Q2 		$39.5K Hold
40,106
– – ﹤0.01% 2361
2025
Q1 		$57.8K Buy
40,106
+10,000
+33% +$18.4K ﹤0.01% 2228
2024
Q4 		$66.2K Sell
30,106
-164
-0.5% -$383 ﹤0.01% 2205
2024
Q3 		$49.9K Buy
30,270
+100
+0.3% +$202 ﹤0.01% 2348
2024
Q2 		$67K Buy
30,170
+1,342
+5% +$3.16K ﹤0.01% 2258
2024
Q1 		$77.3K Hold
28,828
– – ﹤0.01% 2220
2023
Q4 		$86.2K Buy
28,828
+222
+0.8% +$288 ﹤0.01% 2127
2023
Q3 		$28K Hold
28,606
– – ﹤0.01% 2076
2023
Q2 		$39.8K Buy
+28,606
New +$39.9K ﹤0.01% 1975
2020
Q3 		– Sell
-1,171
Closed -$60K – 2133
2020
Q2 		$60K Buy
+1,171
New +$49K ﹤0.01% 1994

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Private Advisor Group's ESPR Position: Q2 2026 in Review

Private Advisor Group reduced its Esperion Therapeutics (ESPR) stake by 16% in Q2 2026, selling an estimated $17.4K and leaving 32,381 shares worth $102K. The position accounts for ﹤0.01% of the portfolio, ranked #2439.

Private Advisor Group first reported a position in ESPR in Q2 2020 and has held it in 14 quarters since. The position peaked at $143K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Private Advisor Group held 32,381 shares of Esperion Therapeutics worth $102K as of Q2 2026.
  • Private Advisor Group sold 6,225 Esperion Therapeutics shares in Q2 2026, an estimated $17.4K.
  • Esperion Therapeutics made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2439 holding.
  • Private Advisor Group first reported a position in Esperion Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • Private Advisor Group's Esperion Therapeutics position peaked at $143K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.